P&K Skin Research Center Co. Ltd (347740) - Cash Flow Conversion Efficiency
Based on the latest financial reports, P&K Skin Research Center Co. Ltd (347740) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.70 Billion ≈ $1.15 Million USD) by net assets (₩81.39 Billion ≈ $55.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See P&K Skin Research Center Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
P&K Skin Research Center Co. Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how P&K Skin Research Center Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
P&K Skin Research Center Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of P&K Skin Research Center Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airtime Partecipazioni SpA
PA:ALMEX
|
0.316x |
|
CTK Co. Ltd
KQ:260930
|
-0.017x |
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
-0.033x |
|
REDCO PRP GROUP LTD -05
F:8KI
|
N/A |
|
Kirklands Inc
NASDAQ:KIRK
|
0.190x |
|
Dabomb Protein
TWO:6578
|
0.000x |
|
Farm Price Holdings Berhad
KLSE:0304
|
0.039x |
|
Lii Hen Industries Bhd
KLSE:7089
|
0.033x |
Annual Cash Flow Conversion Efficiency for P&K Skin Research Center Co. Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of P&K Skin Research Center Co. Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see 347740 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩76.94 Billion ≈ $52.14 Million |
₩9.03 Billion ≈ $6.12 Million |
0.117x | +57.07% |
| 2023-12-31 | ₩74.24 Billion ≈ $50.31 Million |
₩5.55 Billion ≈ $3.76 Million |
0.075x | -29.50% |
| 2022-12-31 | ₩70.81 Billion ≈ $47.98 Million |
₩7.51 Billion ≈ $5.09 Million |
0.106x | -13.13% |
| 2021-12-31 | ₩63.07 Billion ≈ $42.74 Million |
₩7.70 Billion ≈ $5.22 Million |
0.122x | -21.66% |
| 2020-12-31 | ₩55.63 Billion ≈ $37.70 Million |
₩8.67 Billion ≈ $5.87 Million |
0.156x | -41.24% |
| 2019-12-31 | ₩24.50 Billion ≈ $16.60 Million |
₩6.49 Billion ≈ $4.40 Million |
0.265x | -0.76% |
| 2018-12-31 | ₩15.96 Billion ≈ $10.81 Million |
₩4.26 Billion ≈ $2.89 Million |
0.267x | -- |
About P&K Skin Research Center Co. Ltd
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vi… Read more